HIV and ID Observations

August 11th, 2011

Next Single-Pill HIV Treatment Approved, and It’s Not Called “B-Tripla”

One famous HIV clinician/clinical researcher likens co-formulated TDF/FTC/EFV (Atripla) to a “Godzilla,”  so dominant has the treatment become as initial therapy for HIV. He bases his comments on this study done at his institution, showing that in 2007, fully 85% of patients starting treatment in their clinic began TDF/FTC/EFV. Does this big lizard of a […]

---

August 3rd, 2011

Why the Proposed Massachusetts HIV Testing Bill is Bad for Patients

As I’ve written about here multiple times, I’m not a big fan of the HIV testing law in our state. First, there’s the requirement for written informed consent, something that every state (except a couple) has wisely abandoned. Second, it’s more than a testing law — it’s also an HIV privacy law, which is arguably […]

---

July 12th, 2011

A Thank You to Nice Patients

Yesterday I saw one of my favorite long-term patients. She’s just wonderful, and it’s always a joy to see her. Here are some reasons: She’s uniformly nice — not just to me, but to all the nurses and social workers and other support staff in our clinic. She shows up on time for her appointments. […]

---

July 3rd, 2011

Proof That We Are Not French

In case you were worrying about fading American national identity as we celebrate July 4, did you see this detail on a recent E. coli O104:H4 outbreak from France? More recently, at least 15 people in Bordeaux, in southwestern France, appear to have been infected with the strain found in Germany. Most of them have […]

---

June 24th, 2011

Reflections on Levofloxacin as it Goes Generic

With the news that a generic form of levofloxacin has just been approved by the FDA, some thoughts about this remarkable antibiotic: When it was first approved in 1996, levofloxacin was the first oral antibiotic that really covered all common causes of community acquired pneumonia. Strep pneumo, H flu, mycoplasma, legionella, chlamydia — check, check, […]

---

June 19th, 2011

Abacavir Agonistes

The studies on abacavir and its potential association with increased cardiovascular risk have been inconsistent ever since the news first broke at CROI 2008. But recently the data have been swirling around so fast and furious that it seems appropriate to take out this famous Greek epithet. A summary of some recent notable studies: An […]

---

June 15th, 2011

Hockey Helicobacters

Today’s ID/HIV items come to you courtesy of a winter game being played during a summer month: So it appears that community-based care of HCV augmented by telemedicine is just as good as traditional clinic visits to specialists. My first thought on reading this important paper is that there are undoubtedly lots of ways to […]

---

June 13th, 2011

More on Generic Antiretrovirals …

In the recent post on the approval of generic Combivir — and the lack of availability of generic Epivir (lamivudine, 3TC), which was both anticipated and likely to be more useful — I speculated there were several possible causes of this surprising turn of events. But ultimately I concluded, “In sum, the real reason there’s no […]

---

June 2nd, 2011

Original XMRV/CFS Paper Almost, Sort-of Retracted by Science

From the pages of Science In this week’s edition of Science Express, we are publishing two Reports that strongly support the growing view that the association between XMRV and CFS described by Lombardi et al. likely reflects contamination of laboratories and research reagents with the virus … Because the validity of the study by Lombardi et al. […]

---

May 26th, 2011

Surprise! It’s Generic Combivir!

After last week’s unveiling of the new NNRTI rilpivirine, now we have a different kind of drug approval from the FDA: FDA granted approval for a generic formulation fixed dose combination of lamivudine and zidovudine tablets, 150 mg/300 mg, two nucleoside analogue reverse transcriptase inhibitors, indicated in combination with other antiretroviral agents for the treatment […]

---